

# **India Ceftriaxone Market By Dose (100 mg, 200 mg, 250 mg, 500 mg and Others), By Source (In-house v/s Contract Manufacturing Organizations), By Form (Intramuscular Injection, Intravenous Injection, Infusion, Others), By Distribution Channel (Online v/s Offline), By Application (Endocarditis, Meningitis, Pneumonia, Bone and Joint Infections, Intra-Abdominal Infections, Skin Infections, Urinary Tract Infections, Gonorrhoea, Others), By End User (Adult v/s Paediatric), By Region, Competition, Forecast & Opportunities, 2020-2030F**

<https://marketpublishers.com/r/I436B07CAFF0EN.html>

Date: September 2025

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: I436B07CAFF0EN

## **Abstracts**

India Ceftriaxone Market was valued at USD 205.65 Million in 2024 and is expected to reach USD 262.72 Million by 2030, growing with a CAGR of 4.31% in the forecast period. The India Ceftriaxone market has witnessed steady growth in recent years, driven by rising demand for effective antibiotics to treat bacterial infections. Ceftriaxone, a third-generation cephalosporin antibiotic, is widely used across the country due to its broad-spectrum efficacy, especially in treating severe infections such as pneumonia, meningitis, and sepsis. It is available in both oral and injectable forms, with the injectable segment commanding a significant market share due to its rapid therapeutic action and usage in hospital settings.

Increasing incidences of infectious diseases, growing hospital admissions, and the expansion of healthcare infrastructure in both urban and rural regions are fueling the demand for Ceftriaxone. Government initiatives aimed at improving access to essential

medicines and the rising prevalence of antimicrobial resistance have also reinforced the role of Ceftriaxone as a critical antibiotic in clinical practice.

India's position as a major producer of generic pharmaceuticals supports a highly competitive Ceftriaxone market, with numerous domestic players manufacturing and marketing the drug under various brand names. However, challenges such as stringent regulatory compliance, price controls under the National List of Essential Medicines (NLEM), and rising concerns over antibiotic misuse may influence market dynamics.

Despite these challenges, the outlook remains positive due to ongoing investments in pharmaceutical R&D and growing export opportunities. The increasing focus on public health, along with rising awareness of infection control, is expected to sustain demand for Ceftriaxone across hospitals, clinics, and public healthcare programs in India, maintaining its relevance in the antibiotic space.

## **Key Market Drivers**

### **Rising Prevalence of Infectious Diseases**

The rising prevalence of infectious diseases in India is a significant factor driving the demand for antibiotics like Ceftriaxone. Bacterial infections continue to be a leading cause of morbidity and mortality across the country. Respiratory tract infections, including pneumonia, are among the most common, with over 4 million reported cases annually. According to national health data, India experiences an estimated 120,000 deaths from pneumonia each year, especially among children under five and the elderly. These cases often require hospitalization and intravenous antibiotics, making Ceftriaxone a preferred choice due to its broad-spectrum activity.

Typhoid fever also remains a public health concern, with over 1.5 million cases reported annually. In such enteric infections, Ceftriaxone is commonly used when resistance to first-line treatments is observed. Similarly, the burden of urinary tract infections and sexually transmitted infections continues to grow, particularly in densely populated urban areas.

Meningitis, although less common, poses a severe health risk, with thousands of cases reported annually, especially in outbreaks. Ceftriaxone is widely used in both prophylactic and curative settings for meningococcal meningitis. The drug's usage is further supported by the growing number of surgical procedures and hospital-acquired infections, both of which increase the risk of bacterial complications. The prevalence of

multidrug-resistant organisms has led clinicians to rely on Ceftriaxone for serious infections where other antibiotics fail. As infectious diseases persist due to poor sanitation, high population density, and uneven access to healthcare, the use of effective injectable antibiotics like Ceftriaxone remains critical in India's treatment landscape.

## **Key Market Challenges**

### Antimicrobial Resistance (AMR)

Antimicrobial resistance (AMR) poses a critical challenge to the effective use of antibiotics like Ceftriaxone in India. The country has one of the highest burdens of bacterial infections in the world, and the overuse and misuse of antibiotics have significantly contributed to rising resistance levels. Ceftriaxone, once considered highly effective for a range of severe infections, is now encountering reduced efficacy in several clinical settings. According to surveillance data, over 50% of *Escherichia coli* and *Klebsiella pneumoniae* isolates in India show resistance to third-generation cephalosporins such as Ceftriaxone. These pathogens are common causes of urinary tract infections, pneumonia, bloodstream infections, and neonatal sepsis. In neonatal intensive care units across Indian hospitals, high levels of resistance to Ceftriaxone have been reported, complicating treatment protocols.

India is also among the largest consumers of antibiotics globally, with estimates suggesting over 13 billion defined daily doses consumed annually. A substantial proportion of these are used without prescription, especially in rural areas where self-medication and over-the-counter access are common. This widespread misuse accelerates the development of resistant bacterial strains.

The Indian Council of Medical Research (ICMR) has established AMR surveillance networks to track resistance patterns, yet nationwide enforcement of antibiotic stewardship remains inconsistent. Poor infection control practices and inadequate diagnostics in smaller hospitals allow resistant infections to spread unchecked. AMR not only reduces the clinical utility of Ceftriaxone but also increases healthcare costs, prolongs hospital stays, and raises mortality rates. Combating resistance is essential to sustain the effectiveness of critical antibiotics in India's healthcare system.

## **Key Market Trends**

### Increasing Role of Hospital Pharmacies & Retail Shift Online

The role of hospital pharmacies in India has been expanding, driven by the growing number of inpatients, tighter drug quality controls, and centralized procurement policies. Hospital pharmacies now serve as the primary distribution point for critical injectable antibiotics like Ceftriaxone. These facilities ensure availability, manage proper storage conditions, and maintain prescribing discipline through institutional guidelines. In tertiary care hospitals, over 70% of injectable antibiotics are dispensed directly through in-house pharmacies to ensure compliance with prescription protocols. Government hospitals procure Ceftriaxone in bulk through centralized tenders under the National Health Mission or state-specific health schemes. This process channels large volumes of the drug through public hospital pharmacies at subsidized prices. In private hospitals, in-house pharmacies support closed-loop systems that limit misuse and encourage antibiotic stewardship. These institutional settings help track usage patterns, ensure rational drug use, and manage inventory efficiently.

Simultaneously, India is witnessing a rapid shift in retail pharmaceutical sales to online platforms. The online pharmacy market in India was valued at over ₹25,000 crore in 2023 and is projected to grow at over 20% annually. This digital transition is improving access to antibiotics in semi-urban and rural areas, where physical pharmacies may be limited. While injectable antibiotics like Ceftriaxone are prescription-bound and less common in e-pharmacies, oral antibiotics and supportive medications are increasingly sold online. E-commerce platforms, supported by telemedicine services, are also beginning to partner with clinics and diagnostic centers, setting the stage for more integrated digital distribution of essential medicines in the future.

### **Key Market Players**

Radicura Pharmaceuticals Pvt. Ltd

Wockhardt Limited (Taurus)

Nectar Lifesciences Ltd.

Qilu Pharmaceutical India Pvt. Ltd.

Mankind Pharma Ltd.

Fresenius Kabi India Pvt. Ltd.

Virchow Healthcare Private Limited

Orchid Pharma Ltd.

Ikon Remedies Pvt. Ltd.

IPCA Laboratories Ltd

### **Report Scope:**

In this report, the India Ceftriaxone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

#### India Ceftriaxone Market, By Dose:

100 mg

200 mg

250 mg

500 mg

Others

#### India Ceftriaxone Market, By Source:

In-house

Contract Manufacturing Organizations

#### India Ceftriaxone Market, By Form:

Intramuscular Injection

Intravenous Injection

Infusion

Others

India Ceftriaxone Market, By Distribution Channel:

Online

Offline

India Ceftriaxone Market, By Application:

Endocarditis

Meningitis

Pneumonia

Bone and Joint Infections

Intra-Abdominal Infections

Skin Infections

Urinary Tract Infections

Gonorrhoea

Others

India Ceftriaxone Market, By End User:

Adult

Paediatric

India Ceftriaxone Market, By Region:

North India

East India

West India

South India

### **Competitive Landscape**

Company Profiles: Detailed analysis of the major companies present in the India Ceftriaxone Market.

### **Available Customizations:**

India Ceftriaxone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

### **Company Information**

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. INDIA CEFTRIAXONE MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Dose (100 mg, 200 mg, 250 mg, 500 mg and Others)
  - 5.2.2. By Source (In-house v/s Contract Manufacturing Organizations)
  - 5.2.3. By Form (Intramuscular Injection, Intravenous Injection, Infusion, Others)
  - 5.2.4. By Distribution Channel (Online v/s Offline)

5.2.5. By Application (Endocarditis, Meningitis, Pneumonia, Bone and Joint Infections, Intra-Abdominal Infections, Skin Infections, Urinary Tract Infections, Gonorrhoea, Others)

5.2.6. By End User (Adult v/s Paediatric)

5.2.7. By Region (North India, South India, East India, West India)

5.2.8. By Company (2024)

5.3. Market Map

## **6. NORTH INDIA CEFTRIAXONE MARKET OUTLOOK**

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Dose

6.2.2. By Source

6.2.3. By Form

6.2.4. By Distribution Channel

6.2.5. By Application

6.2.6. By End User

## **7. SOUTH INDIA CEFTRIAXONE MARKET OUTLOOK**

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Dose

7.2.2. By Source

7.2.3. By Form

7.2.4. By Distribution Channel

7.2.5. By Application

7.2.6. By End User

## **8. EAST INDIA CEFTRIAXONE MARKET OUTLOOK**

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Dose

8.2.2. By Source

- 8.2.3. By Form
- 8.2.4. By Distribution Channel
- 8.2.5. By Application
- 8.2.6. By End User

## **9. WEST INDIA CEFTRIAXONE MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Dose
  - 9.2.2. By Source
  - 9.2.3. By Form
  - 9.2.4. By Distribution Channel
  - 9.2.5. By Application
  - 9.2.6. By End User

## **10. MARKET DYNAMICS**

- 10.1. Drivers
- 10.2. Challenges

## **11. MARKET TRENDS & DEVELOPMENTS**

- 11.1. Merger & Acquisition (If Any)
- 11.2. Product Launches (If Any)
- 11.3. Recent Developments

## **12. INDIA ECONOMIC PROFILE**

## **13. INDIA CEFTRIAXONE MARKET: SWOT ANALYSIS**

## **14. COMPETITIVE LANDSCAPE**

- 14.1. Radicura Pharmaceuticals Pvt. Ltd.
  - 14.1.1. Business Overview
  - 14.1.2. Company Snapshot
  - 14.1.3. Products & Services
  - 14.1.4. Financials (As Reported)

- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Wockhardt Limited (Taurus)
- 14.3. Nectar Lifesciences Ltd.
- 14.4. Qilu Pharmaceutical India Pvt. Ltd.
- 14.5. Mankind Pharma Ltd.
- 14.6. Fresenius Kabi India Pvt. Ltd.
- 14.7. Virchow Healthcare Private Limited
- 14.8. Orchid Pharma Ltd.
- 14.9. Ikon Remedies Pvt. Ltd.
- 14.10. IPCA Laboratories Ltd.

## **15. STRATEGIC RECOMMENDATIONS**

## **16. ABOUT US & DISCLAIMER**

## I would like to order

Product name: India Ceftriaxone Market By Dose (100 mg, 200 mg, 250 mg, 500 mg and Others), By Source (In-house v/s Contract Manufacturing Organizations), By Form (Intramuscular Injection, Intravenous Injection, Infusion, Others), By Distribution Channel (Online v/s Offline), By Application (Endocarditis, Meningitis, Pneumonia, Bone and Joint Infections, Intra-Abdominal Infections, Skin Infections, Urinary Tract Infections, Gonorrhoea, Others), By End User (Adult v/s Paediatric), By Region, Competition, Forecast & Opportunities, 2020-2030F

Product link: <https://marketpublishers.com/r/l436B07CAFF0EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l436B07CAFF0EN.html>